Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) is pleased to announce that it received 3rd place prize for “Innovation Prize” at an entrepreneurship support program in the biotechnology field held by Nippon Boehringer Ingelheim Co ., Ltd. (Representative Director, Chairman and President: Yoshiaki Aono).

■ Outline of this Award
Craif’s project “Comprehensive analysis of urinary exosomal miRNA profiles for patient classification” was selected as one of the four most innovative and outstanding projects in the “Innovation Prize,” a program organized by Nippon Boehringer Ingelheim to support entrepreneurs. The “Innovation Prize” is a program that supports researchers, entrepreneurs, and start-up companies working on innovative drug discovery to realize their ideas, commercialize their products, and nurture their seeds under the vision of “Value through Innovation.”

■ Comments from CEO

　Craif is a startup company founded in 2018. “NANO IP™ (NANO Intelligence Platform),” enables highly accurate detection of biological material such as microRNAs, related to diseases by using non-invasively collected bodily fluids, like urine. With this innovative platform, Craif is dedicated to developing screening tests using NANO IP™ to achieve early detection of cancer and provide the best medicine for everybody.
　With this award, we will explore the possibility to collaborate with pharmaceutical companies, and contribute to society through drug discovery.